Initial Beneficial Ownership · 3/A
Attovia Therapeutics, Inc.
Initial Beneficial Ownership
Structured filing — 3/A
form3a-10082026_111032.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-08-04
- Original submission
- 2026-08-04
- Issuer
- Attovia Therapeutics, Inc.
- Issuer CIK
- 0002058707
- Trading symbol
- ATTO
Reporting owner 1
- Name
- Fu Tao
- Reporting owner CIK
- 0001644888
- Relationship
- Director · Officer
- Officer title
- President and CEO
- Address
- C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS, CA, 94070
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 87,843 | D | |
| Common Stock | 99,181 | I | By Trust[F1] |
| Common Stock | 116,103 | I | By Trust[F2] |
| Common Stock | 245,425 | I | By Trust[F3] |
Table key
- D
- Direct
- I
- Indirect
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 1.5793 | [F4] | 2033-08-16 | Common Stock | 23,437 | D |
| Stock Option (Right to Buy) | 3.5302 | [F5] | 2034-05-08 | Common Stock | 409,709 | D |
| Stock Option (Right to Buy) | 4.9237 | [F6] | 2035-05-17 | Common Stock | 370,290 | D |
Table key
- D
- Direct
Footnotes
- F1
- These shares are held by the TF 2025 Annuity Trust, of which the reporting person is the trustee.↩ 1
- F2
- These shares are held by the TF 2026 Annuity Trust, of which the reporting person is the trustee.↩ 1
- F3
- These shares are held by the Hai Fu Revocable Trust, of which the reporting person and Hai Fu are trustees.↩ 1
- F4
- Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of June 2, 2023, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.↩ 1
- F5
- Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of May 9, 2024, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.↩ 1
- F6
- Vest with respect to 25% of the shares of common stock underlying the stock option on the one year anniversary of May 18, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service through such date.↩ 1
Remarks
This Form 3 amendment amends the Form 3 filed on August 4, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 3 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.
Signature 1
- Signed
- /s/ Steven Chan, Attorney-in-Fact for Tao Fu
- Date
- 2026-10-08
Filed exhibits
- EX-24 ↗ex24-10082026_111033.htm
Company context
We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care. Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31 (IL-31) that completed dosing in a Phase 1 clinical trial in healthy volunteers (HVs) and patients in the first quarter of 2026. ATTO-2306 is an ATTOBODY-based bispecific targeting interleukin-13 (IL-13) and IL-31 that is in investigational new drug (IND)-enabling studies, and we expect to commence a Phase 1 clinical trial in the first half of 2027. Lastly, ATTO-1091 is our trispecific ATTOBODY-based Fc fusion protein that is designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, and is currently in IND-enabling studies.